PHILADELPHIA — The Greenwall Foundation has named Penn Medicine’s Peter Reese, MD, MSCE, a leading voice for improving organ donor rates and access to transplant, as a 2013 Greenwall Faculty Scholar in Bioethics.
The Greenwall Faculty Scholars Program supports research that goes beyond current work in bioethics to help resolve pressing ethical issues in clinical care, biomedical research, and public policy. Dr. Reese, who is an Assistant Professor of Medicine and Epidemiology at Penn, is one of four innovative thinkers in the nation this year to receive the prestigious honor.
Among other projects, he will conduct a randomized controlled trial of novel methods to improve the rates of donor registration.
The Greenwall Foundation supports this career development program to enable faculty to carry out original research on policy and moral dilemmas at the intersection of ethics and the life sciences. Scholars will receive 50 percent salary support for three years to develop their research program.
Dr. Reese, who takes care of kidney transplant recipients and living kidney donors, focuses on developing effective strategies to increase access to kidney and liver transplantation. His research is motivated by the widening gap between the number of patients wait-listed for transplants and the limited number of organs available. He uses tools from epidemiology, biostatistics, health services research and medical ethics to describe disparities in transplantation and methods to overcome them. Through policy development work with the United Network for Organ Sharing, he also helps to translate clinical research into effective national policy.
Dr. Reese has written specifically about barriers to live donor transplantation, the impact of functional status on kidney transplant outcomes, and the implications of organ allocation policies for the elderly. His work was among the first to examine the practice and ethical implications of accepting live kidney donors with risk factors for kidney disease.
In recognition of his contributions to transplant research, he received a Presidential Early Career Award for Scientists and Engineers in July 2012, the highest honor bestowed by the United States Government on science and engineering professionals in the early stages of their independent research careers.
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, excellence in patient care, and community service. The organization consists of the University of Pennsylvania Health System and Penn’s Raymond and Ruth Perelman School of Medicine, founded in 1765 as the nation’s first medical school.
The Perelman School of Medicine is consistently among the nation's top recipients of funding from the National Institutes of Health, with $550 million awarded in the 2022 fiscal year. Home to a proud history of “firsts” in medicine, Penn Medicine teams have pioneered discoveries and innovations that have shaped modern medicine, including recent breakthroughs such as CAR T cell therapy for cancer and the mRNA technology used in COVID-19 vaccines.
The University of Pennsylvania Health System’s patient care facilities stretch from the Susquehanna River in Pennsylvania to the New Jersey shore. These include the Hospital of the University of Pennsylvania, Penn Presbyterian Medical Center, Chester County Hospital, Lancaster General Health, Penn Medicine Princeton Health, and Pennsylvania Hospital—the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.
Penn Medicine is an $11.1 billion enterprise powered by more than 49,000 talented faculty and staff.